

Appl. No. : **Unknown**
Filed : **herewith**

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: October 18, 2011

By: Che S. Chereskin
Che Swyden Chereskin
Registration No. 41,466
Agent of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

Appl. No. : ~~Unknown~~
 Filed : herewith

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 9-11, 14 and 18 have been amended as follows:

Claim 9. (Amended) Use of A method of suppressing formation of memory cells of the immune system of a mammal in need thereof, comprising administering IL-15 inhibiting or eliminating compounds for the manufacture of a pharmaceutical composition for manipulating memory cells of the immune system to the mammal.

Claim 10. (Amended) Use of IL-15 inhibiting or eliminating compounds A method according to claim 9 wherein the memory cells are CD4⁺ T lymphocytes.

Claim 11. (Amended) Use of IL-15 inhibiting or eliminating compounds A method according to claim 9 or 10 wherein said compound is selected from the group consisting of an anti-IL-15 antibody, anti-IL-15R α antibody, fragments of these antibodies, e.g. the Fab or F(ab') $_2$ fragment, soluble IL-15R α , fusion proteins consisting of comprising soluble IL-15R α and Fc fragment, compounds, e.g. peptides, binding and/or inhibiting functional IL-15 receptor, IL-15 antisense oligonucleotides.

Claim 14. (Amended) Pharmaceutical composition A method according to claim 12 or 13 for use in the treatment of auto-immune diseases or in treatment before, during or after transplantation.

Claim 18. (Amended) Pharmaceutical composition A method according to claim 16-9 for use in the treatment of immune deficiency diseases or in treatment before, during or after vaccination.